Menu Back toSession-0501-Drug-Safety-in-Clinical-Development-Benefit-Risk-Based-Decision

The 7th DIA China Annual Meeting

Session 0501 Drug Safety in Clinical Development – Benefit / Risk Based Decision

Session Chair(s)

Yuan  Meng

Yuan Meng

  • Director, Associate Safety Risk Lead (Associate SR
  • Pfizer (China) Research and Development Co.,Ltd, China

Safety Surveillance& Risk Management in Drug Development


Mason  Shih

Mason Shih

  • Site Head, Drug Safety, Asia Pacific
  • Genentech, a Member of Roche Group, China
Ayman  Ayoub, MD, MSc

Safety Surveillance& Risk Management in Drug Development

Ayman Ayoub, MD, MSc

  • Executive Director
  • Pfizer LTD Central Research, United Kingdom
Mason  Shih

The Value of Drug Safety in Drug Development

Mason Shih

  • Genentech Inc., United States

Contact us

For exhibition, advertising and hosting inquiry, please contact:
Jean XU:, or Sofie Peeters:
Tel: +86 10 5923 1096

For general inquiry, please contact DIA China office:
Tel: +86 10 5704 2650